Research Paper Volume 15, Issue 4 pp 1177—1198
A novel fatty-acid metabolism-based classification for triple negative breast cancer
Figure 8. The role of FS scheme in anti-PD-1/L1 immunotherapy. (A) Survival analyses for low- and high-FS subgroups in the anti-PD-L1 immunotherapy cohort (IMvigor 210). (B) The proportion of patients with response/nonresponse to PD-L1 blockade immunotherapy in low and high FS groups (IMvigor 210). (C) The proportion of patients with different therapeutic responses to PD-L1 blockade in low and high FS groups (IMvigor 210). (D) The proportion of patients with different immunity phenotypes in low and high FS groups (IMvigor 210). (E) The proportion of patients with different survival status in low and high FS groups (GSE78220). (F) The proportion of patients with different therapeutic response to PD-1 blockade immunotherapy in low and high FS groups (GSE78220). Abbreviations: SD: stable disease; PD: progressive disease; CR: complete response; PR: partial response.